Triple Combination Therapy Proves Effective For Treating Hypertension

Triple Combination Therapy Proves Effective For Treating Hypertension

Editor's Choice
Main Category: Hypertension
Article Date: 02 May 2012 - 13:00 PDT

email to a friend   printer friendly   opinions   <!-- rate article

Patient / Public:

Healthcare Prof:

Results from two studies were presented at the 22nd European Society of Hypertension (ESH) in London highlighting the benefits of triple combination therapy for individuals suffering from hypertension.

The results add to clinical understanding of olmesartan(O)/amlodipine(A)/hydrochlorothiazide(H) (O/A/H) triple combination therapy (Sevikar HCT®).

About 15 to 20% of patients with hypertension are not controlled by dual therapy. Given that many of these patients will subsequently require triple combination therapy, means that further proof of this approach's efficacy is welcome.

O/A/H is a single pill that contains three anti-hypertensive agents and is indicated for the treatment of individuals with hypertension. The pill contains the following three agents:

• olmesartan medoxomil (OLM) - a long-acting selective angiotensin II receptor blocker
• amlodipine (AML) - a calcium channel blocker
• hydrochlorothiazide (HCTZ) - a diuretic

Professor Massimo Volpe, of the University of Rome, explained:

"These additional analyses further build understanding of how the adjunctive use of this triple combination therapy can benefit patients. Effective lowering of blood pressure is central to reducing cardiovascular risk in hypertension patients.

These data show that triple combination therapy delivers reliable blood pressure reduction across the spectrum of hypertension management."

Professor Reinhold Kreutz, acting director of the Institute of Clinical Pharmacology and Toxicology in Berlin, presented the first analysis of a 10 week study.

The study found that more participants with moderate to severe hypertension achieved normal/high-normal blood pressure (BP) levels (120/80-

Both O/A/H combination therapy and O/A therapy were well-tolerated and no new safety concerns were identified. According to results from the study O/A/H therapy is the next logical step in the hypertension treatment for individuals who do not respond to dual O/A therapy.

A second analysis of Professor Lars-Christian Rump's 32 week study revealed that participants with moderate to severe hypertension who had not achieved their blood pressure goal after receiving O/A/H 40/10/12.5 for 8 weeks achieved significantly better 24-hour ambulatory blood pressure control and during the daytime when uptitrated to O/A/H 40/10/25 mg (weeks 24-32).

For patients with hypertension, the original blood pressure goal was diabetes, chronic renal or chronic cardiovascular disease the goal was

Both dosages were well tolerated, and the study results provide further evidence that patients who are not responding on the lower dose of triple O/A/H can benefit from receiving the higher dose. In addition, the results highlight the flexibility of the triple combination therapy in individuals not responding to current treatment.

Professor Volpe also present another study which evaluated changes in systolic blood pressure (SBP) from baseline in individuals suffering from moderate-to severe hypertension after receiving triple O/A/H therapy for 54 weeks. The study included patients with a very high SBP.

Results from the study indicate that open-label long-term O/A/H treatment was effective and was able to reduce SBP in almost all participants with normal-to-high normal range of 120-

Results from these studies add to previously published TRINITY study findings. Results from TRINITY revealed that triple O/A/H was more effective in lowering blood pressure and that more patients reached the current recommended blood pressure target than patients assigned to dual combination regardless of age, gender, race, and hypertension severity.

Also at the ESH was the launch of a new European patient website. The Hypertension Care website, www.hypertensioncare.eu, provides information and support regarding hypertension and is available for patients in Europe. At present the website is not available for patients in the United Kingdom.

The new website expands upon a healthcare professional site launched last year by Daiichi Sankyo Europe. The website is packaged in an easy to use format and simple language and provides information on all aspects of hypertension care and prevention. In addition, the website focuses oh physicians and patients working effectively together to improve compliance.

According to results from a study conducted in 2008, 50% of patients still stick to their treatment after one year. Patients with hypertension who adhere to their treatment are at lower risk of cardiovascular outcomes than patients who don't adhere to treatment.

Reinhard Bauer, CEO of Daiichi Sankyo Europe, explains:

"The website demonstrates Daiichi Sankyo's continued commitment to listening to the needs of patients and physicians and offers tools and services that provide them with added support when dealing with their condition."

Written By Grace Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

• Additional
• References
• Citations

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

---

APA

---

Please note: If no author information is provided, the source is cited instead.

---

Add Your Opinion On This Article

'Triple Combination Therapy Proves Effective For Treating Hypertension'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.